Last reviewed · How we verify
PEG-Intron + Ribavirin
PEG-Intron is a pegylated form of interferon-alpha, which is used to stimulate the body's immune response to fight viral infections, while Ribavirin is an antiviral medication that works by inhibiting viral replication.
PEG-Intron is a pegylated form of interferon-alpha, which is used to stimulate the body's immune response to fight viral infections, while Ribavirin is an antiviral medication that works by inhibiting viral replication. Used for Chronic hepatitis C, Chronic hepatitis B.
At a glance
| Generic name | PEG-Intron + Ribavirin |
|---|---|
| Also known as | Peginterferon alfa-2b |
| Sponsor | PharmaEssentia |
| Drug class | Interferon-alpha and antiviral |
| Target | Interferon receptors |
| Modality | Small molecule |
| Therapeutic area | Hepatology |
| Phase | Phase 3 |
Mechanism of action
PEG-Intron works by binding to interferon receptors on the surface of cells, triggering a signaling cascade that activates immune cells and increases the production of antiviral proteins. Ribavirin, on the other hand, is a nucleoside analog that is incorporated into viral RNA, causing chain termination and preventing viral replication.
Approved indications
- Chronic hepatitis C
- Chronic hepatitis B
Common side effects
- Flu-like symptoms
- Fatigue
- Headache
- Depression
- Anemia
Key clinical trials
- Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients (PHASE3)
- A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C (PHASE1)
- Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy (PHASE3)
- Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C (PHASE3)
- Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy (PHASE3)
- Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected Patients (PHASE3)
- HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin (PHASE3)
- Evaluating Safety and Efficacy In Hepatitis C Patients After PegIntron Pen Treatment (Study P04896)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |